Robust 2002 sales seen in foreign-invested pharmaceutical firms

Published: 2003-04-07 06:59:00

Updated: 2003-04-07 06:59:00

Despite initial perspective that the domestic pharmaceutical industry would suffer a serious setback in its projected turnover and growth last year, the majority of foreign-invested pharmaceutical firms fared well in terms of turnover and net income, thanks to their innovative new drugs. Details:...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK